284 related articles for article (PubMed ID: 26794137)
1. Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial.
Arbel Y; Klempfner R; Erez A; Goldenberg I; Benzekry S; Shlomo N; Fisman EZ; Tenenbaum A;
Cardiovasc Diabetol; 2016 Jan; 15():11. PubMed ID: 26794137
[TBL] [Abstract][Full Text] [Related]
2. Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease: Twenty-Two-Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry.
Klempfner R; Erez A; Sagit BZ; Goldenberg I; Fisman E; Kopel E; Shlomo N; Israel A; Tenenbaum A
Circ Cardiovasc Qual Outcomes; 2016 Mar; 9(2):100-8. PubMed ID: 26957517
[TBL] [Abstract][Full Text] [Related]
3. Metabolic syndrome is independently associated with increased 20-year mortality in patients with stable coronary artery disease.
Younis A; Younis A; Tzur B; Peled Y; Shlomo N; Goldenberg I; Fisman EZ; Tenenbaum A; Klempfner R
Cardiovasc Diabetol; 2016 Oct; 15(1):149. PubMed ID: 27793156
[TBL] [Abstract][Full Text] [Related]
4. Decrease in triglyceride level by bezafibrate is related to reduction of recurrent coronary events: a Bezafibrate Infarction Prevention substudy.
Haim M; Benderly M; Boyko V; Goldenberg I; Tanne D; Battler A; Goldbourt U; Behar S;
Coron Artery Dis; 2006 Aug; 17(5):455-61. PubMed ID: 16845254
[TBL] [Abstract][Full Text] [Related]
5. Association of Bezafibrate Treatment With Reduced Risk of Cancer in Patients With Coronary Artery Disease.
Iakobishvili Z; Hasin T; Klempfner R; Shlomo N; Goldenberg I; Brenner R; Kornowski R; Gerber Y
Mayo Clin Proc; 2019 Jul; 94(7):1171-1179. PubMed ID: 31272567
[TBL] [Abstract][Full Text] [Related]
6. Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry.
Haim M; Benderly M; Brunner D; Behar S; Graff E; Reicher-Reiss H; Goldbourt U
Circulation; 1999 Aug; 100(5):475-82. PubMed ID: 10430760
[TBL] [Abstract][Full Text] [Related]
7. Bezafibrate treatment is associated with a reduced rate of re-hospitalization in smokers after acute coronary syndrome.
Klempfner R; Goldenberg I; Fisman EZ; Amit U; Haitovich A; Matetzky S; Medvedofsky D; Shemesh J; Tenenbaum A
Cardiol J; 2014; 21(4):364-9. PubMed ID: 24142677
[TBL] [Abstract][Full Text] [Related]
8. The Association of Body Mass Index and 20-Year All-Cause Mortality Among Patients With Stable Coronary Artery Disease.
Younis A; Younis A; Goldkorn R; Goldenberg I; Peled Y; Tzur B; Klempfner R
Heart Lung Circ; 2019 May; 28(5):719-726. PubMed ID: 29581037
[TBL] [Abstract][Full Text] [Related]
9. Determining triglyceride reductions needed for clinical impact in severe hypertriglyceridemia.
Christian JB; Arondekar B; Buysman EK; Jacobson TA; Snipes RG; Horwitz RI
Am J Med; 2014 Jan; 127(1):36-44.e1. PubMed ID: 24384100
[TBL] [Abstract][Full Text] [Related]
10. Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease?
Tenenbaum A; Boyko V; Fisman EZ; Goldenberg I; Adler Y; Feinberg MS; Motro M; Tanne D; Shemesh J; Schwammenthal E; Behar S
Cardiovasc Diabetol; 2008 Jun; 7():18. PubMed ID: 18565233
[TBL] [Abstract][Full Text] [Related]
11. Effect of the metabolic syndrome and hyperuricemia on outcome in patients with coronary artery disease (from the Bezafibrate Infarction Prevention Study).
Brodov Y; Behar S; Boyko V; Chouraqui P
Am J Cardiol; 2010 Dec; 106(12):1717-20. PubMed ID: 21126615
[TBL] [Abstract][Full Text] [Related]
12. The effect of bezafibrate and omega-3 fatty acids on lymphocyte cytokine release and systemic inflammation in patients with isolated hypertriglyceridemia.
Krysiak R; Gdula-Dymek A; Okopien B
Eur J Clin Pharmacol; 2011 Nov; 67(11):1109-17. PubMed ID: 21630032
[TBL] [Abstract][Full Text] [Related]
13. Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial.
Goldenberg I; Benderly M; Goldbourt U;
J Am Coll Cardiol; 2008 Jan; 51(4):459-65. PubMed ID: 18222357
[TBL] [Abstract][Full Text] [Related]
14. High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study.
Arcavi L; Behar S; Caspi A; Reshef N; Boyko V; Knobler H
Am Heart J; 2004 Feb; 147(2):239-45. PubMed ID: 14760320
[TBL] [Abstract][Full Text] [Related]
15. Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial.
Goldenberg I; Boyko V; Tennenbaum A; Tanne D; Behar S; Guetta V
Arch Intern Med; 2009 Mar; 169(5):508-14. PubMed ID: 19273782
[TBL] [Abstract][Full Text] [Related]
16. Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) Registry: high triglycerides constitute an independent risk factor.
Tanne D; Koren-Morag N; Graff E; Goldbourt U
Circulation; 2001 Dec; 104(24):2892-7. PubMed ID: 11739302
[TBL] [Abstract][Full Text] [Related]
17. Hypertriglyceridemia and the fibrate trials.
Faergeman O
Curr Opin Lipidol; 2000 Dec; 11(6):609-14. PubMed ID: 11086334
[TBL] [Abstract][Full Text] [Related]
18. Activated platelets in patients with severe hypertriglyceridemia: effects of triglyceride-lowering therapy.
de Man FH; Nieuwland R; van der Laarse A; Romijn F; Smelt AH; Gevers Leuven JA; Sturk A
Atherosclerosis; 2000 Oct; 152(2):407-14. PubMed ID: 10998469
[TBL] [Abstract][Full Text] [Related]
19. Impaired Fasting Glucose Is the Major Determinant of the 20-Year Mortality Risk Associated With Metabolic Syndrome in Nondiabetic Patients With Stable Coronary Artery Disease.
Younis A; Goldkorn R; Goldenberg I; Geva D; Tzur B; Mazu A; Younis A; Fisman Z; Tannenbaum A; Klempfner R
J Am Heart Assoc; 2017 Oct; 6(11):. PubMed ID: 29079562
[TBL] [Abstract][Full Text] [Related]
20. Effects of bezafibrate on lipoprotein subclasses and inflammatory markers in patients with hypertriglyceridemia--a nuclear magnetic resonance study.
Ikewaki K; Noma K; Tohyama J; Kido T; Mochizuki S
Int J Cardiol; 2005 Jun; 101(3):441-7. PubMed ID: 15907413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
